Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous infusion solutions for drug delivery in home and ambulatory care settings. Its Freedom Syringe Infusion System includes Freedom60 and FreedomEDGE syringe infusion drivers, Precision Flow Rate Tubing, and HigH-Flo Subcutaneous Safety Needle Sets.
Company updates commonly cover quarterly results, revenue guidance, cash flow trends, FDA 510(k) clearances, EU MDR certification, and label expansions, including FreedomEDGE use for RYSTIGGO delivery. News also addresses pharma services and clinical-trial collaborations with biopharmaceutical companies, customization of the Freedom System across drug categories, and governance or leadership succession matters.
KORU Medical Systems (NASDAQ: KRMD) reported second quarter 2026 net revenues of $12.0 million, up 18.2% year over year, driven by 12.4% growth in domestic core and 59.1% growth in international core revenues. Pharma services and clinical trials revenues declined 35% to $0.6 million.
Gross profit rose 21.2% to $7.8 million with gross margin of 65.1%. Net income was $0.25 million versus a $0.21 million loss a year ago, and adjusted EBITDA was $0.9 million. The company acquired a connected monitoring technology asset and entered a multi-year supply agreement.
KORU Medical withdrew its U.S. 510(k) for FreedomEDGE with Phesgo and shifted its U.S. oncology strategy to alternative higher-volume molecules. Updated 2026 guidance calls for $47.5–$48.5 million in revenue (15–18% growth), gross margin of 62–64%, positive adjusted EBITDA, and year-end cash above $7.5 million.
KORU Medical Systems (NASDAQ: KRMD) will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. Company management is scheduled to present at 10:00 a.m. ET, with a live and archived webcast available on the News/Events page of the Investors section of its website.
KORU Medical Systems (NASDAQ: KRMD) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to review the results and provide a corporate update for investors.
KORU Medical (NASDAQ: KRMD) presented real-world data on its FreedomEDGE syringe infusion system at the 51st Annual Oncology Nursing Society Congress.
The multi-site study across four U.S. community infusion centers reported 100% successful dosing, reduced nurse strain, high nurse (4.85/5) and patient (4.92/5) satisfaction, and workflow benefits.
KORU’s FREEDOM system supports 5–50mL+ subcutaneous infusions and is used by 59,000+ patients for over 3M infusions annually, with a 97% adherence rate, 9 on-label drugs, and approval in 30+ countries.
KORU Medical (NASDAQ: KRMD) reported Q1 2026 net revenues of $11.8M, up 22.1% year‑over‑year, with gross profit of $7.2M and gross margin of 61.5%.
Net loss narrowed to ($0.8M) and cash totaled $8.8M as of March 31, 2026. The company reiterated full‑year 2026 revenue guidance of $47.5M–$50.0M and gross margin guidance of 61%–63%.
KORU Medical (NASDAQ: KRMD) will report first quarter 2026 financial results on Wednesday, May 6, 2026. Management will host a conference call and live webcast at 4:30 p.m. ET to discuss results and provide a corporate update.
Call dial-ins: (877) 407-0784 (U.S./Canada) and (201) 689-8560 (international). A live and archived webcast will be available via the investor relations calendar at www.korumedical.com; the archive will remain available for six months.
KORU Medical Systems (NASDAQ: KRMD) announced EU MDR certification for its Freedom60® Infusion Pump, including the 50 mL prefilled syringe adapter, enabling commercialization across the European Union. Freedom60 complements the FreedomEDGE® system (20 mL syringe compatibility) to expand prefilled syringe options for subcutaneous immunoglobulin (SCIg) therapy.
The certification aims to simplify home infusion, reduce preparation and handling steps, and broaden patient access to intuitive large-volume subcutaneous delivery across Europe.
KORU Medical (NASDAQ: KRMD) announced a planned CEO transition: Linda Tharby will retire effective June 30, 2026, and Adam Kalbermatten, currently Chief Commercial Officer, will assume the CEO role effective July 1, 2026 (appointed President effective March 15, 2026).
Under Tharby, the company doubled its recurring patient base to over 55,000, expanded internationally, broadened the Freedom infusion platform beyond immunoglobulin, delivered consistent revenue growth, and achieved profitability. Tharby will remain on the board and advise through the end of 2026.
KORU Medical (NASDAQ: KRMD) reported strong 2025 results with full-year net revenues of $41.1M (up 22%) and fourth-quarter revenues of $10.9M (up 23%). Gross profit rose to $25.6M with 62.3% margin. Net loss improved to $2.6M and adjusted EBITDA turned positive at $0.6M. Ending cash was $8.9M. The company received a 510(k) clearance, announced EU MDR certification, expanded pharma collaborations, and initiated 2026 guidance of $47.5–$50.0M revenue with positive adjusted EBITDA and cash flow.
KORU Medical Systems (NASDAQ: KRMD) will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026.
Management will host a conference call and live webcast at 4:30 p.m. ET. Dial-in numbers and a live/archived webcast are available via the company's investor relations calendar at www.korumedical.com. The archived webcast will be available for six months.